For Women Over 50, AI Could Change Breast Cancer Treatment Decisions
For women over 50, a breast cancer diagnosis often comes with a difficult and deeply personal question: Do you really need chemotherapy?
In early-stage, hormone receptor–positive (HR+) breast cancer — the most common type diagnosed in postmenopausal women — the answer isn’t always clear. Chemotherapy can reduce the risk of recurrence for some patients. For others, it may offer little benefit while introducing significant side effects.
Read: The New Global Standard for Menopause Care
Discover: More important health articles
New data presented at the San Antonio Breast Cancer Symposium (SABCS) suggests that may be starting to change.
Artera released findings from multiple studies validating its multimodal artificial intelligence (MMAI) platform, showing it can predict both a patient’s risk of cancer spreading. The data spans more than 7,000 patients across Phase III clinical trials conducted in North America and Europe — with findings that are especially relevant for women over 50.
A Common Dilemma For Postmenopausal Women
Breast cancer risk increases with age, and many women diagnosed after menopause fall into a treatment gray area. While their cancer may not be considered highly aggressive, the risk of recurrence still leads many clinicians to recommend chemotherapy as a precaution.
That approach, however, can come at a cost.
“Traditional approaches can result in patients, especially those who are post-menopausal with node-negative tumors, receiving chemotherapy with limited benefit while still facing significant toxicities,” said Prof. Nadia Harbeck, director of the Breast Center at LMU University Hospital in Munich. “It’s exciting to witness the emergence of new technologies that allow us to deliver the optimal breast cancer care.”
What The AI Model Shows
Artera’s MMAI platform analyzes digitized tumor images alongside clinical data to assess cancer aggressiveness and predict treatment benefit.
Across the studies:
- Approximately 68% of patients were classified as low risk, with about a 95% chance of remaining free from distant metastasis over 10 years
- Postmenopausal women were successfully stratified into low-, intermediate- and high-risk groups with clear differences in outcomes
- In patients age 50 and older, chemotherapy benefit varied significantly based on risk classification
In one key analysis, MMAI high-risk patients over 50 experienced a 52% reduction in distant metastasis when treated with chemotherapy, while MMAI low-risk patients saw no added benefit.
For women in this age group, that distinction is critical.
Moving Toward More Personalized Care
“Advancing precision medicine means ensuring every patient can benefit from individualized care,” said Andre Esteva, CEO of Artera AI. “As we validate this technology across countries and cancer types, we’re showing that precision medicine can be more personalized and accessible while helping clinicians avoid unnecessary treatments without added time, cost, or complex processes.”
Unlike other testing methods, the AI model is designed to work with data already collected during diagnosis, offering a faster and more accessible way to guide treatment decisions.
Why This Matters For Women Over 50
For years, many women over 50 have had to make chemotherapy decisions without clear, individualized data — often choosing treatment as a precaution rather than based on certainty.
The findings presented at SABCS point to a shift.
With more precise risk stratification, clinicians can better identify which patients are likely to benefit from chemotherapy — and which are not.
For women navigating a diagnosis later in life, that could mean fewer unnecessary treatments, more confidence in care decisions and a more personalized approach at a stage when quality of life matters as much as outcomes.
As tools like this continue to be validated across large clinical trials, the future of breast cancer treatment may become less about broad assumptions — and more about what each individual patient actually needs.
